ProfileGDS5678 / 1426404_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 91% 92% 91% 92% 93% 88% 92% 92% 90% 93% 92% 91% 91% 91% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.4509391
GSM967853U87-EV human glioblastoma xenograft - Control 27.6298192
GSM967854U87-EV human glioblastoma xenograft - Control 37.4644291
GSM967855U87-EV human glioblastoma xenograft - Control 47.7137892
GSM967856U87-EV human glioblastoma xenograft - Control 57.8468993
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.6298388
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.3662592
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.4799192
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.2635890
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.7869493
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.4841592
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.4688191
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.4187691
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.4770891